Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female child-bearing potential must have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of child-bearing potential, as defined above, must have a negative urine or serum pregnancy within  days prior to receiving the first dose of study medication; if a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential has a negative serum or urine pregnancy within  hours prior to receiving the first dose of study medication
COHORT : Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
COHORT : Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
SAFETY RUN-IN: Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
RANDOMIZED PHASE II CLINICAL TRIAL: Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of child-bearing potential must have a negative urine pregnancy test within  hours prior to receiving the first dose of study medication. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy test within  days of treatment registration; female subjects of childbearing potential should have a negative urine or serum pregnancy test repeated within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female participants of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential has a negative serum or urine pregnancy within  hours prior to receiving the first dose of study medication
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of HiDAC treatment and again prior to D of pembrolizumab treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is to be treated with MK- (pembrolizumab)
INCLUSION CRITERIA FOR STRATUM C: Female subjects of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is to be treated with MK- (pembrolizumab)
Female participants of childbearing potential must have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study drug. If the urine test is positive, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female patients of childbearing potential should have a negative urine or serum pregnancy within  hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication and agree to use effective contraception; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of DCBA; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy prior to receiving the first study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication (cycle , day ) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential as defined in Section .. must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication or study indicated ultrasound treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female and male subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through  days after the last dose of study medication. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication for female subjects of childbearing age
Female subject of childbearing potential should have a negative urine or serum pregnancy within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
STUDY TREATMENT: Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential has a negative serum or urine pregnancy within  hours prior to receiving the first dose of study medication
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy at screening and within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication (cycle , day ) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication, pembrolizumab (cycle , day ) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication (cycle , day ) (female subjects of childbearing potential); if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Participants of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential require a negative pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours of study enrollment up to administration of the dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of pembrolizumab; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative serum pregnancy test within  hours prior to receiving first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours of study enrollment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patient of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (hCG) within  hours prior to first doses of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy test within  hours of receiving first dose of study treatment; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test <  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have two negative urine or serum pregnancy test, one at - days before first dose of study drug and another within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Women of childbearing potential must plan to have a urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a negative serum pregnancy test will be required
Female subjects of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study drug; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and subject also should agree to use an adequate method of contraception starting with screening through  days after the last dose of study therapy (if sexually active).
Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative urine or serum pregnancy test within  hours prior to taking study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as (by other than medical reasons):
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving retreatment with study medication
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female participants of childbearing potential must have a negative serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  weeks prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subjects of childbearing potential as defined in Section .. must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Negative urine or serum pregnancy test within  days before Day  (first dose of study medication) if female subject is of childbearing potential (WOCBP).
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy test within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential must have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female subject of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Female patients of childbearing potential should have a negative urine or serum pregnancy within  hours prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
